RESPINOR DXT - improving clinical decision-making for patients on Ventilation Support
Godkjenningen dokumenterer en skattefradragsordning, men kilden publiserer ikke faktisk skattefradrag per prosjekt.
Prosjektopplysninger
- Prosjektperiode
- Instrument
- Skatte-/avgiftsfordel
- Støttegiver
- SkatteFUNN / Norges forskningsråd
- Vedtaksdato
- Program/aktivitet
- SkatteFUNN
- Prosjekttype
- SkatteFUNN-prosjekt
- Kommune
- Oslo
- Fylke
- Oslo
Offentlig prosjektsammendrag
RESPINOR is developing the first non-invasive, ultrasound-based medical device for early detection of diaphragm dysfunction (DD) and continuous monitoring of diaphragm function, RESPINOR DXT (Diaphragm Excursion Technology). The diaphragm is the main breathing muscle and accounts for 70% of the air we breathe in. Yet, there are no standardized or objective technologies for continuous monitoring of the diaphragm available. RESPINOR aims to optimize time on MV. There are many critical decisions that face intensive care specialists relating to respiratory function and ventilation; to intubate or re-intubate patients, predict weaning failure or success, and detection and mitigation of patient-ventilator asynchrony (PVA) for non-invasively ventilated (NIV) adult and neonatal patients. PVA is defined as a mismatch between the demands of the patient's respiratory system regarding time, flow, volume, or pressure and the supply from the ventilator and occurs in up to 80% of adult patients receiving NIV and 86% in preterm neonates. NIV is the preferred treatment, as it is less aggressive than MV and associated with better outcomes in terms of mortality and short and long-term complications. Clinicians are seeking a safe, accurate, and reliable synchronized NIV mode to prevent intubation and avoid lung injury. Through a successful project, DXT has the potential to reduce intubation rates and the associated risk of infections, reduce chronic impairment of respiratory function, and thereby reduce mortality. Each year up to 15 million patients are admitted to an ICU in the EU and US. Of these, more than 2 million patients receive MV, and 1.3 million patients NIV. There is a significant unmet medical need for new non-invasive technologies for continuous monitoring of the diaphragm in the ICU and NICU. RESPINOR's strategy is to fully capitalize on the current window of opportunity, and our goal is to become the standard-of-care for diaphragm monitoring.
Kilde og proveniens
SkatteFUNN publiserer prosjektidentitet, periode, eier og godkjenningsstatus uten prosjektbeløp.
Åpne prosjektet i ProsjektbankenMottaker kobles med organisasjonsnummer. Program og prosjektidentitet forblir kildeavgrenset.
Ikke publisert er en egen tilstand og betyr verken null eller ukjent utbetaling.